Амбулаторне лікування пацієнтів із діабетичною нейропатією альфа-ліпоєвою кислотою. Який шлях введення препарату обрати?
Main Article Content
Abstract
Визначення. Класифікація
Діабетична нейропатія — одне з найпоширеніших ускладнень цукрового діабету (ЦД), що діагностується у більшості пацієнтів (Tesfaye S. et al., 2010). На нашу думку, ті або інші порушення діяльності нервової системи спостерігаються в кожного пацієнта з ЦД, тому коректніше трактувати ці зміни не як ускладнення, а як неврологічні прояви захворювання.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
References
Бреговский В.Б., Посохина О.В., Карпова И.А. Предикторы эффективности лечения диабетической полинейропатии нижних конечностей альфа-липоевой кислотой // Терапевтич. архив. — 2005. — № 10. — С. 15-19.
Комелягина Е.Ю., Волковой А.К., Мыскина Н.А., Анциферов М.Б. Сравнительная эффективность различных режимов перорального приема тиоктовой кислоты в терапии болевой формы диабетической дистальной нейропатии // Фарматека. — 2006. — 17. — 89-94.
Храмилин В.Н., Демидова И.Ю., Игнатова О.Ю. Оценка эффективности различных режимов пероральной терапии альфа-липоевой кислотой болевой формы диабетической периферической полинейропатии // Сахарный диабет. — 2010. — № 2. — С. 3-7.
Ametov A., Barinov A., O’Brien P. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipolic acid: the SYDNEY trial // Diabetes Care. — 2003. — Vol. 26. — P. 770-776.
Attal N., Cruccu G., Haanpaa M. et al. EFNS guidelines on pharmacological treatment of neuropathic pain // Eur. J. Neurol. — 2006. — 13. — 1153-69.
Boulton A.J., Vinik A.I., Arezzo J.C. et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association // Diabetes Care. — 2005. — 28. — 956-962.
Dyck P.J., Davies J.L., Clark V.M., Litchy W.J. et al. Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes // Diabetes Care. — 2006. — 29. — 2282-2288.
Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society // J. Peripher. Nerv. Syst. — 2010. — 15. — 79-92.
Llewelyn J.G., Tomlinson D.R., Thomas P.K. Diabetic Neuropathies. In Peripheral Neuropathy. — 4th ed. / Ed. by P.J. Dyck, P.K. Thomas. — Philadelphia: Elsevier, 2005. — Р. 1951-1992.
Reljanovic M., Reichel G., Rett K. et al. Treatment of diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II) // Free Radic. Res. — 1999. — Vol. 31. — P. 171-179.
Tesfaye S. et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments // Diabetes Care. — 2010. — 33. — 2285-2293.
Treede R.D., Jensen T.S., Campbell J.N., Cruccu G. et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes // Neurology. — 2008. — 70. — 1630-1635.
Ziegler D., Hanefeld M., Ruhnau K.J. et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized conrolled trial (ALADIN study) // Diabetologia. — 1995. — 38. — 1425-33.
Ziegler D., Hanefeld M., Ruhnau K.J. et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic A in Diabetic neuropathy // Diabetes Care. — 1999 Aug. — 22(8). — 1296-301.